| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 福安药业(集团)股份有限公司是一家主要从事单环β-内酰胺类、青霉素类、头孢类抗生素原料药及制剂的研发、生产和销售企业.公司主要产品包括氨曲南原料药及制剂,替卡西林钠、磺苄西林钠原料药,头孢硫脒、头孢唑肟钠制剂,其中氨曲南原料药及制剂为公司主导产品.公司已拥有发明专利3项,已受理发明专利7项,国家新药证书6份,药品批准文号58个,全部剂型的生产车间均已通过GMP认证.公司氨曲南原料药先后获得重庆市重点新产品、国家重点新产品、重庆市高新技术产品称号,2009年市场占有率达48.09%,位居行业首位;氨曲南制剂为重庆市高新技术产品,2009年市场占有率达11.37%,位居行业第二位.替卡西林钠原料药为国家三类新药,先后获得重庆市重点新产品、重庆市高新技术产品、重庆市优秀重点新产品称号,2009年市场占有率为79.41%,在国内市场中处于主导地位。 | ||||||||||||||||||||||||
| Main Business | 化学药品的研发、生产、销售 | ||||||||||||||||||||||||
| Legal Representative | 汪天祥 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 汤沁 | ||||||||||||||||||||||||
| Solicitors | 上海东方华银律师事务所 | ||||||||||||||||||||||||
| Auditors | 北京永拓会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 023-61213003 | ||||||||||||||||||||||||
| Fax No | 023-68573999 | ||||||||||||||||||||||||
| Website | www.fapharm.com | ||||||||||||||||||||||||
| fapharm.@fapharm.com；tangqin@fapharm.com；taoyadong@fapharm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 22/03/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.190 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.050 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.484 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.210B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |